Neurocrine Biosciences, Inc. (NBIX)
USD 94.89
(4.42%)
USD 94.89
(4.42%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.84 Billion USD | 26.06% |
| 2022 | 1.46 Billion USD | 30.94% |
| 2021 | 1.11 Billion USD | 8.05% |
| 2020 | 1.03 Billion USD | 32.68% |
| 2019 | 780.7 Million USD | 74.91% |
| 2018 | 446.35 Million USD | 178.32% |
| 2017 | 160.37 Million USD | 867.33% |
| 2016 | -20.9 Million USD | -48.96% |
| 2015 | -14.03 Million USD | 2.56% |
| 2014 | -14.4 Million USD | -32.34% |
| 2013 | -10.88 Million USD | -126.19% |
| 2012 | 41.54 Million USD | -46.34% |
| 2011 | 77.41 Million USD | 131.08% |
| 2010 | 33.5 Million USD | 1034.47% |
| 2009 | 2.95 Million USD | -25.71% |
| 2008 | 3.97 Million USD | 224.75% |
| 2007 | 1.22 Million USD | -96.88% |
| 2006 | 39.23 Million USD | -68.33% |
| 2005 | 123.88 Million USD | 45.45% |
| 2004 | 85.17 Million USD | -38.76% |
| 2003 | 139.07 Million USD | 670.73% |
| 2002 | 18.04 Million USD | -56.25% |
| 2001 | 41.24 Million USD | 145.69% |
| 2000 | 16.78 Million USD | -11.19% |
| 1999 | 18.9 Million USD | 6.78% |
| 1998 | 17.7 Million USD | -35.4% |
| 1997 | 27.4 Million USD | 35.64% |
| 1996 | 20.2 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 502.49 Million USD | -0.83% |
| 2024 Q2 | 574.6 Million USD | 14.35% |
| 2024 Q3 | 614.1 Million USD | 6.87% |
| 2023 Q1 | 411.9 Million USD | 1.88% |
| 2023 Q4 | 506.7 Million USD | 3.92% |
| 2023 FY | 1.84 Billion USD | 26.06% |
| 2023 Q3 | 487.6 Million USD | 10.52% |
| 2023 Q2 | 441.2 Million USD | 7.11% |
| 2022 Q4 | 404.3 Million USD | 5.89% |
| 2022 FY | 1.46 Billion USD | 30.94% |
| 2022 Q2 | 373.4 Million USD | 22.03% |
| 2022 Q3 | 381.8 Million USD | 2.25% |
| 2022 Q1 | 306 Million USD | -0.62% |
| 2021 Q1 | 233.7 Million USD | -4.61% |
| 2021 Q4 | 307.9 Million USD | 5.52% |
| 2021 Q3 | 291.8 Million USD | 2.1% |
| 2021 Q2 | 285.8 Million USD | 22.29% |
| 2021 FY | 1.11 Billion USD | 8.05% |
| 2020 Q2 | 300 Million USD | 27.66% |
| 2020 Q4 | 245 Million USD | -4.22% |
| 2020 FY | 1.03 Billion USD | 32.68% |
| 2020 Q1 | 235 Million USD | -2.73% |
| 2020 Q3 | 255.8 Million USD | -14.73% |
| 2019 Q2 | 181.97 Million USD | 32.56% |
| 2019 FY | 780.7 Million USD | 74.91% |
| 2019 Q1 | 137.27 Million USD | 5.63% |
| 2019 Q3 | 219.86 Million USD | 20.82% |
| 2019 Q4 | 241.6 Million USD | 9.89% |
| 2018 FY | 446.35 Million USD | 178.32% |
| 2018 Q3 | 150.2 Million USD | 56.38% |
| 2018 Q4 | 129.95 Million USD | -13.48% |
| 2018 Q1 | 70.13 Million USD | -25.19% |
| 2018 Q2 | 96.05 Million USD | 36.95% |
| 2017 Q2 | 6.27 Million USD | 0.0% |
| 2017 Q4 | 93.75 Million USD | 55.38% |
| 2017 FY | 160.37 Million USD | 867.33% |
| 2017 Q3 | 60.34 Million USD | 861.76% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | 15 Million USD | 0.0% |
| 2016 Q2 | - USD | -100.0% |
| 2016 FY | -20.9 Million USD | -48.96% |
| 2016 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | -100.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | 19.76 Million USD | 0.0% |
| 2015 FY | -14.03 Million USD | 2.56% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | -14.4 Million USD | -32.34% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | -100.0% |
| 2013 FY | -10.88 Million USD | -126.19% |
| 2013 Q4 | 730 Thousand USD | 0.14% |
| 2013 Q3 | 729 Thousand USD | -0.14% |
| 2013 Q2 | 730 Thousand USD | 0.0% |
| 2013 Q1 | 730 Thousand USD | -96.67% |
| 2012 Q3 | 9.35 Million USD | -11.47% |
| 2012 Q4 | 21.94 Million USD | 134.55% |
| 2012 FY | 41.54 Million USD | -46.34% |
| 2012 Q2 | 10.56 Million USD | -6.2% |
| 2012 Q1 | 11.26 Million USD | 1.41% |
| 2011 Q3 | 41.63 Million USD | 242.47% |
| 2011 Q4 | 11.11 Million USD | -73.32% |
| 2011 FY | 77.41 Million USD | 131.08% |
| 2011 Q1 | 12.51 Million USD | -8.38% |
| 2011 Q2 | 12.15 Million USD | -2.84% |
| 2010 Q4 | 13.65 Million USD | -5.47% |
| 2010 Q3 | 14.44 Million USD | 211.18% |
| 2010 FY | 33.5 Million USD | 1034.47% |
| 2010 Q2 | 4.64 Million USD | 516.6% |
| 2010 Q1 | 753 Thousand USD | 1.76% |
| 2009 Q1 | 747 Thousand USD | 2.47% |
| 2009 FY | 2.95 Million USD | -25.71% |
| 2009 Q3 | 733 Thousand USD | 0.0% |
| 2009 Q4 | 740 Thousand USD | 0.95% |
| 2009 Q2 | 733 Thousand USD | -1.87% |
| 2008 Q2 | 734 Thousand USD | -58.08% |
| 2008 Q4 | 729 Thousand USD | -4.2% |
| 2008 FY | 3.97 Million USD | 224.75% |
| 2008 Q1 | 1.75 Million USD | 229.14% |
| 2008 Q3 | 761 Thousand USD | 3.68% |
| 2007 FY | 1.22 Million USD | -96.88% |
| 2007 Q1 | 104 Thousand USD | -98.9% |
| 2007 Q4 | 532 Thousand USD | -1.48% |
| 2007 Q3 | 540 Thousand USD | 1025.0% |
| 2007 Q2 | 48 Thousand USD | -53.85% |
| 2006 Q2 | 9.24 Million USD | -52.54% |
| 2006 Q4 | 9.44 Million USD | 778.96% |
| 2006 FY | 39.23 Million USD | -68.33% |
| 2006 Q3 | 1.07 Million USD | -88.38% |
| 2006 Q1 | 19.47 Million USD | 38.02% |
| 2005 FY | 123.88 Million USD | 45.45% |
| 2005 Q3 | 64.74 Million USD | 95.2% |
| 2005 Q1 | 11.86 Million USD | -35.82% |
| 2005 Q2 | 33.16 Million USD | 179.58% |
| 2005 Q4 | 14.11 Million USD | -78.21% |
| 2004 FY | 85.17 Million USD | -38.76% |
| 2004 Q1 | 16.94 Million USD | -37.57% |
| 2004 Q2 | 15.04 Million USD | -11.17% |
| 2004 Q3 | 34.7 Million USD | 130.59% |
| 2004 Q4 | 18.48 Million USD | -46.73% |
| 2003 Q2 | 44.96 Million USD | 19.23% |
| 2003 FY | 139.07 Million USD | 670.73% |
| 2003 Q3 | 29.25 Million USD | -34.93% |
| 2003 Q4 | 27.13 Million USD | -7.26% |
| 2003 Q1 | 37.71 Million USD | 872.56% |
| 2002 Q3 | 4.98 Million USD | 17.89% |
| 2002 FY | 18.04 Million USD | -56.25% |
| 2002 Q4 | 3.87 Million USD | -22.18% |
| 2002 Q2 | 4.22 Million USD | -14.73% |
| 2002 Q1 | 4.95 Million USD | -61.37% |
| 2001 Q2 | 3.32 Million USD | -4.59% |
| 2001 Q3 | 21.59 Million USD | 548.83% |
| 2001 FY | 41.24 Million USD | 145.69% |
| 2001 Q1 | 3.48 Million USD | -15.44% |
| 2001 Q4 | 12.83 Million USD | -40.57% |
| 2000 FY | 16.78 Million USD | -11.19% |
| 2000 Q2 | 3.47 Million USD | 5.49% |
| 2000 Q4 | 4.12 Million USD | -29.92% |
| 2000 Q3 | 5.88 Million USD | 69.24% |
| 2000 Q1 | 3.29 Million USD | -31.31% |
| 1999 Q1 | 4.2 Million USD | -14.29% |
| 1999 Q2 | 4.2 Million USD | 0.0% |
| 1999 Q3 | 5.7 Million USD | 35.71% |
| 1999 FY | 18.9 Million USD | 6.78% |
| 1999 Q4 | 4.8 Million USD | -15.79% |
| 1998 Q2 | 2.7 Million USD | -40.0% |
| 1998 Q1 | 4.5 Million USD | -31.82% |
| 1998 FY | 17.7 Million USD | -35.4% |
| 1998 Q4 | 4.9 Million USD | -12.5% |
| 1998 Q3 | 5.6 Million USD | 107.41% |
| 1997 Q1 | 9.1 Million USD | -5.21% |
| 1997 Q3 | 6.5 Million USD | 27.45% |
| 1997 Q4 | 6.6 Million USD | 1.54% |
| 1997 FY | 27.4 Million USD | 35.64% |
| 1997 Q2 | 5.1 Million USD | -43.96% |
| 1996 Q1 | 2.4 Million USD | 0.0% |
| 1996 FY | 20.2 Million USD | 0.0% |
| 1996 Q2 | 5.7 Million USD | 137.5% |
| 1996 Q3 | 2.5 Million USD | -56.14% |
| 1996 Q4 | 9.6 Million USD | 284.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | -466.393% |
| Embecta Corp. | 749.9 Million USD | -146.353% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | -505.104% |
| Dynavax Technologies Corporation | 182.11 Million USD | -914.403% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -2428.364% |
| Pacira BioSciences, Inc. | 490.3 Million USD | -276.783% |
| PainReform Ltd. | -15 Thousand USD | 12316100.0% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -6109.33% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -22053.281% |
| SCYNEXIS, Inc. | 124.51 Million USD | -1383.653% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -333383.161% |
| Cosmos Health Inc. | 4.34 Million USD | -42373.174% |
| Journey Medical Corporation | 52.52 Million USD | -3417.45% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -22053.281% |
| Safety Shot Inc | -74.45 Thousand USD | 2481263.625% |
| Alpha Teknova, Inc. | 10.29 Million USD | -17842.89% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | -329.004% |
| Bright Green Corporation | -237.01 Thousand USD | 779541.05% |
| Procaps Group, S.A. | 239.56 Million USD | -671.135% |
| Theratechnologies Inc. | 62.12 Million USD | -2873.491% |
| Harrow Health, Inc. | 90.55 Million USD | -1940.131% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -38833.614% |
| Biofrontera Inc. | 16.62 Million USD | -11010.844% |
| DURECT Corporation | 6.83 Million USD | -26944.357% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -252.731% |
| Cronos Group Inc. | 6.99 Million USD | -26325.797% |
| OptiNose, Inc. | 62.35 Million USD | -2862.761% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | -318.76% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 609802.97% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -60387.733% |
| Organogenesis Holdings Inc. | 309.79 Million USD | -496.339% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -34145.883% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -5416.95% |
| Radius Health, Inc. | 307.71 Million USD | -500.369% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -18231.236% |
| ProPhase Labs, Inc. | 16.23 Million USD | -11276.316% |
| Phibro Animal Health Corporation | 312.48 Million USD | -491.193% |
| Procaps Group S.A. | 239.56 Million USD | -671.135% |
| Alvotech | -69.42 Million USD | 2761.116% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -141789.401% |
| Viatris Inc. | 6.43 Billion USD | 71.307% |
| Rockwell Medical, Inc. | 8.7 Million USD | -21124.724% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -3284.384% |
| SIGA Technologies, Inc. | 122.09 Million USD | -1413.12% |
| Tilray Brands, Inc. | 223.35 Million USD | -727.129% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -4314.337% |
| Shineco, Inc. | 882.16 Thousand USD | -209315.894% |
| PetIQ, Inc. | 252.74 Million USD | -630.949% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 247877.593% |
| Incannex Healthcare Limited | 12 Thousand USD | -15394900.0% |
| Alimera Sciences, Inc. | 61.17 Million USD | -2920.108% |
| Silver Spike Investment Corp. | 8.1 Million USD | -22700.092% |
| Assertio Holdings, Inc. | 125.04 Million USD | -1377.341% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 27123870.371% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -43978.405% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -28078.768% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 76750.004% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -6712.701% |
| Hempacco Co., Inc. | -1.21 Million USD | 152045.21% |
| Talphera, Inc. | -4.89 Million USD | 37840.552% |
| Alvotech | -69.42 Million USD | 2761.116% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | -733.386% |
| Lantheus Holdings, Inc. | 709.54 Million USD | -160.365% |
| Currenc Group, Inc. | 17.35 Million USD | -10543.971% |
| Kamada Ltd. | 52.59 Million USD | -3412.652% |
| Indivior PLC | 907 Million USD | -103.682% |
| Evoke Pharma, Inc. | 4.97 Million USD | -37005.692% |
| Flora Growth Corp. | 17.73 Million USD | -10314.928% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 76750.004% |
| Evolus, Inc. | 140.52 Million USD | -1214.632% |
| HUTCHMED (China) Limited | 453.55 Million USD | -307.318% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | -437.085% |
| Akanda Corp. | 111.44 Thousand USD | -1657519.18% |